Title:The Role of Tumor Suppressor DLC-1: Far From Clear
VOLUME: 17 ISSUE: 7
Author(s):Xu Liu, Yao-Jie Pan, Jun-Nian Zheng* and Dong-Sheng Pei*
Affiliation:Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, China, 84 West Huai-hai Road, Xuzhou, Jiangsu
Keywords:DLC-1, tumor suppressor, RhoGAP activity, biomarker, GTPase, therapeutic target.
Abstract:Background: Deleted in liver cancer 1 (DLC-1) In human was originally isolated from rats brain and
was often found to be deleted in hepatocellular carcinoma (HCC).
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research literature using
a focused review question and inclusion/exclusion criteria.
Results: Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as
well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1
as a potential tumor suppressor. Additionally, the RhoGAP (Rho-GTPase activating proteins) activity was found
to play a pivotal role in regulating DLC-1.
Conclusion: Although emerging studies in a variety of cancers have identified DLC-1 and its downstream
signaling molecules as potential therapeutic targets for treatments of DLC-1-related cancers, the mechanisms
linked to DLC-1 remain undefined.
